ArticleNature communications2021
Seven-month kinetics of SARS-CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 184 citations in OpenAlex.
- Patient and donor antibody profiles in early COVID-19 convalescent plasma therapy in the COnV-ert trial.Frontiers in immunology · 2025Trial
- Trial
- Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers.EBioMedicine · 2022Trial
- Trial
- Pre-vaccine sentinel antibodies predict blunted vaccine responses.Cell press blue · 2026Article
- An integrative approach for studying immunological variation in an aging population - The Milieu Intérieur follow-up study.Nature communications · 2026Article
- SARS-CoV-2 seroprevalence among pregnant women during the first three waves of the COVID-19 pandemic in southern Mozambique.BMC pregnancy and childbirth · 2026Observational
- A Longitudinal Exploratory Study of SARS-CoV-2 Antibody Dynamics in Young Adults in Bogotá: Lessons from Natural Infection and Post-Vaccination Memory.Biomedicines · 2026Article
- SARS-CoV-2 crossreactive B-cells outnumber seasonal coronavirus spike-specific clones at the end of the COVID-19 pandemic.Npj viruses · 2026Article
- Determinants of long-term SARS-CoV-2 immune responses in asymptomatic-to-moderate COVID-19 patients in sub-Saharan Africa.BMC medicine · 2026Article
- Serological evaluation of coronavirus IgA and IgG antibodies in a repeated cross-sectional cohort of unvaccinated and vaccinated pregnant individuals over three months following SARS-CoV-2 infection.Microbiology spectrum · 2026Article
- Article
- Primary SARS-CoV-2 exposure by vaccination or infection shapes immune responses to omicron variants among a Spanish cohort.Nature communications · 2025Article
- Seasonal Coronavirus-Induced Immunological Imprinting and Previous Herpesvirus Infections in Patients With Long COVID.Journal of medical virology · 2025Article
- The Effect of Preexisting Coronavirus Antibodies on Severe Acute Respiratory Syndrome Coronavirus 2 Infection Outcomes in Exposed Household Members.The Journal of infectious diseases · 2025Article
- Determinants of antibody levels and protection against omicron BQ.1/XBB breakthrough infection.Communications medicine · 2025Article
- Endemic coronavirus infection is associated with SARS-CoV-2 Fc receptor-binding antibodies.Journal of virology · 2025Article
- SARS-CoV-2 incidence, seroprevalence, and antibody dynamics in a rural, population-based cohort: March 2020-July 2022.American journal of epidemiology · 2025Article
- Incidence of dynamic seroconversion in subjects received the first dose of the SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa, Democratic Republic of Congo: prospective cohort study.BMC infectious diseases · 2025Article
- Stability of cytokine and immunoglobulin concentrations in the general population: prepandemic basal concentrations and intraindividual changes until the COVID-19 pandemic.Frontiers in public health · 2025Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 9 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and the individual characteristics influencing it, including the impact of pre-existing antibodies to human coronaviruses causing common cold (HCoVs), is essential to understand protective immunity to COVID-19 and devise effective surveillance strategies. IgM, IgA and IgG levels against six SARS-CoV-2 antigens and the nucleocapsid antigen of the four HCoV (229E, NL63, OC43 and HKU1) were quantified by Luminex, and antibody neutralization capacity was assessed by flow cytometry, in a cohort of health care workers followed up to 7 months (N = 578). Seroprevalence increases over time from 13.5% (month 0) and 15.6% (month 1) to 16.4% (month 6). Levels of antibodies, including those with neutralizing capacity, are stable over time, except IgG to nucleocapsid antigen and IgM levels that wane. After the peak response, anti-spike antibody levels increase from ~150 days post-symptom onset in all individuals (73% for IgG), in the absence of any evidence of re-exposure. IgG and IgA to HCoV are significantly higher in asymptomatic than symptomatic seropositive individuals. Thus, pre-existing cross-reactive HCoVs antibodies could have a protective effect against SARS-CoV-2 infection and COVID-19 disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.